Topic: drug approvals

Electromicrograph showing an HIV-infected T cell in blue and yellow

5. Trogarzo

Trogarzo represents the first HIV therapy with a new mechanism of action approved in more than a decade.
Erleada

4. Erleada

Erleada was greenlighted for non-metastatic, castration-resistant prostate cancer months before its decision date, giving it a big head start on market share compared to its main competitor, Pfizer and Astellas’ Xtandi, which was approved for the same indication in July.
Novartis headquarters

1. Lutathera

Less than three months after agreeing to acquire Advanced Acclerator Applications, Novartis got an FDA OK for Lutathera.